Skip to main content
. 2019 Dec 13;56(2):470–479. doi: 10.3892/ijo.2019.4940

Figure 1.

Figure 1

miR-20b is increased in NSCLC cell lines and clinical samples. (A) Relative expression level of miR-20b in NSCLC cell lines, PC-9, H1975, A549 and H1299, and in BEAS-2B cells determined by RT-qPCR. **P<0.01 and ***P<0.001 vs. BEAS-2B. (B) Expression level of miR-20b in the plasma of NSCLC patients (n=20) and healthy donors (n=20) determined by RT-qPCR. miR-20b expression detected by RT-qPCR in (C) PC-9 and (D) H1975 NSCLC cells transfected with miR-20b mimics, miR-20b inhibitor or associated controls. **P<0.01 and ***P<0.001 vs. miR-control. Data are presented as the mean ± SEM. RT-qPCR, reverse transcription-quantitative PCR; miR, microRNA; NSCLC, non-small cell lung cancer.